The Lustgarten Foundation is the largest private funder of the world’s preeminent pancreatic cancer researchers.
To date, we have funded more than $250 million in research grants and been a leading force in every major advancement in pancreatic cancer research.
Progress is paramount. We drive bold, innovative research with the singular mission: transforming pancreatic cancer into a curable disease.
Lustgarten Announcements
Over 500 pancreatic cancer supporters united at Hudson River Park’s Pier 84 in New York City New York, N.Y. —Over 500 pancreatic cancer supporters united at Hudson River Park’s Pier 84 in Manhattan on April 16 for a morning of hope, remembrance, and action to raise critical funds for the Lustgarten Foundation. Since its inception […]
In 2022, your generosity fueled Lustgarten-funded researchers’ significant progress in pancreatic cancer research. Together, we are advancing research from the laboratory to the clinic faster than ever before, giving renewed hope to patients and their families. We have funded 318 research projects across 81 academic institutions, improving the lives of countless impacted individuals. As Lustgarten […]
Bologna, Italy – On April 3, 2023, Andrew Rakeman, PhD, and Elizabeth Jaffee, MD, attended the first ever Alma Mater Studiorum/Lustgarten Foundation Lecture in Bologna, Italy at the University of Bologna, led by Professor Riccardo Casadei, MD, Chief of the Pancreatic and Endocrine Surgical Division. The lecture entitled “Pancreatic Cancer: The Commitment of Breakthrough Science […]
News From The Field
In the near future, this implantable nanofluidic device could be a game changer in treating pancreatic cancer. Nanomedicine experts at Houston Methodist Academic Institute developed the device.
The microbiome is a term used for the collection of microbes, including microorganisms like bacteria, that live on or in the human body. Jordan Kharofa, MD, said there was little known about the microbiome of long-term pancreatic cancer survivors.
In an effort to bring new compounds to the pancreatic cancer drug development pipeline, Alec Kimmelman, MD, PhD, a professor in and the Anita Steckler and Joseph Steckler Chair of the Department of Radiation Oncology at NYU Grossman School of Medicine and a member of the senior leadership team at NYU Langone Health’s Perlmutter Cancer Center, has received a […]
SUSAN’s story
From Nurse to Patient
When Susan was diagnosed with pancreatic cancer, cutting-edge drugs and a supportive medical team helped her go from patient to survivor. Now she raises funds for continued research through a Lustgarten Foundation Walk for Research.
Read Susan’s Story
